Dihydropyrimidine-thiones and clioquinol synergize to target beta-amyloid cellular pathologies through a metal-dependent mechanism

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Amyloid-β peptide-induced cytotoxicity and mitochondrial dysfunction in yeast.

  2015cited by this paper
• Systematic humanization of yeast genes reveals conserved functions and genetic modularity

  2015cited by this paper
• Yeast transformation by the LiAc/SS carrier DNA/PEG method.

  2014cited by this paper
• Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease

  2014cited by this paper
• Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease.

  2014cited by this paper
• HTSeq—a Python framework to work with high-throughput sequencing data

  2014cited by this paper
• Genome-wide analysis of Saccharomyces cerevisiae identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid-β42: importance of lipid homeostasis

  2014cited by this paper
• Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

  2013cited by this paper
• Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in Neurons

  2013cited by this paper
• TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

  2013cited by this paper
• Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

  2013cited by this paper
• Harnessing the power of yeast to unravel the molecular basis of neurodegeneration

  2013cited by this paper
• Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease

  2013cited by this paper
• 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.

  2012cited by this paper
• Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.

  2012cited by this paper
• Therapeutic redistribution of metal ions to treat Alzheimer's disease.

  2012cited by this paper
• A Predictable Worm: Application of Caenorhabditis elegans for Mechanistic Investigation of Movement Disorders

  2012cited by this paper
• Latrepirdine (Dimebon™) Enhances Autophagy and Reduces Intracellular GFP-Aβ42 Levels in Yeast

  2012cited by this paper
• Differential expression analysis for sequence count data

  2011cited by this paper
• Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease

  2011cited by this paper
• Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer’s Disease Risk Factors in Yeast

  2011cited by this paper
• Metal Complexes of Diisopropylthiourea: Synthesis, Characterization and Antibacterial Studies

  2011cited by this paper
• Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

  2011cited by this paper
• PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

  2010cited by this paper
• Genome-wide analysis of genetic loci associated with Alzheimer disease.

  2010cited by this paper
• Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models

  2010cited by this paper
• Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?

  2010cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Metalloproteins and metal sensing

  2009cited by this paper
• How do bacterial cells ensure that metalloproteins get the correct metal?

  2009cited by this paper
• A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity

  2008cited by this paper
• Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

  2008cited by this paper
• Chaperone-dependent amyloid assembly protects cells from prion toxicity

  2008cited by this paper
• Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.

  2008cited by this paper
• Faculty Opinions recommendation of Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.

  2007cited by this paper
• Alzheimer's Abeta fused to green fluorescent protein induces growth stress and a heat shock response.

  2007cited by this paper
• Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae.

  2007cited by this paper
• The redox chemistry of the Alzheimer's disease amyloid beta peptide.

  2007cited by this paper
• [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen].

  2007cited by this paper
• Flanking sequences profoundly alter polyglutamine toxicity in yeast.

  2006cited by this paper
• The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

  2005cited by this paper
• Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

  2001cited by this paper
• Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

  2000cited by this paper
• Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae

  1999cited by this paper
• Vacuole Biogenesis in Saccharomyces cerevisiae: Protein Transport Pathways to the Yeast Vacuole

  1998cited by this paper
• Increased Neuronal Endocytosis and Protease Delivery to Early Endosomes in Sporadic Alzheimer’s Disease: Neuropathologic Evidence for a Mechanism of Increased β-Amyloidogenesis

  1997cited by this paper
• Evidence for Cu(II) Reduction as a Component of Copper Uptake by Saccharomyces cerevisiae(*)

  1995cited by this paper
• Basic culture methods.

  1995cited by this paper
• Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

  1994cited by this paper
• Preparation of Yeast RNA

  1993cited by this paper
• The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.

  1993cited by this paper
• Ferric reductase of Saccharomyces cerevisiae: molecular characterization, role in iron uptake, and transcriptional control by iron.

  1992cited by this paper
• [Genetics of Caenorhabditis elegans].

  1989cited by this paper

• No citing papers are available for this paper.